International Clinical Trial: A Single-Arm, Multicenter, Phase II Clinical Study Protocol of Sintilimab Combined with Anlotinib and TP Regimen Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Geneva, Feb. 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119085) titled 'A Single-Arm, Multicenter, Phase II Clinical Study Protocol of Sintilimab Combined with Anlotinib and TP Regimen Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma' on Feb. 14.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Mianyang Central Hospital

Condition: Head and Neck Squamous Cell Carcinoma, HNSCC

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2026-02-16

Target Sample Size: experimental group:25;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=302692

Disclaimer: Curated b...